The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase II study of eribulin mesylate (E) with or without pembrolizumab (P) for hormone receptor-positive (HR+) metastatic breast cancer (MBC).
 
Sara M. Tolaney
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Celldex; Eisai; Genentech; Immunomedics; Lilly; Merck; NanoString Technologies; Nektar; Novartis; Pfizer; Puma Biotechnology; Sanofi; Tesaro
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cyclacel (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Lilly (Inst); Merck (Inst); NanoString Technologies (Inst); Nektar (Inst); Novartis (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Celldex; Eisai; Genentech/Roche; Immunomedics; Lilly; Merck; NanoString Technologies; Nektar; Novartis; Pfizer; Puma Biotechnology
 
Romualdo Barroso-Sousa
Consulting or Advisory Role - Lilly
Speakers' Bureau - Roche
 
Tanya Keenan
No Relationships to Disclose
 
Lorenzo Trippa
No Relationships to Disclose
 
Jiani Hu
No Relationships to Disclose
 
Ines Maria Vaz Duarte Luis
Honoraria - AstraZeneca; Kephren; Novartis
Consulting or Advisory Role - Ipsen
 
Gerburg M. Wulf
Stock and Other Ownership Interests - Selecta Biosciences (I)
Research Funding - Merck
Patents, Royalties, Other Intellectual Property - Pin1 as a marker for abnormal cell growth Patent number: 8129131
 
Laura Spring
Honoraria - Dava Oncology
Consulting or Advisory Role - Novartis
Research Funding - Tesaro (Inst)
Travel, Accommodations, Expenses - Novartis
 
Natalie Faye Sinclair
No Relationships to Disclose
 
Chelsea Andrews
No Relationships to Disclose
 
Jessica Demeo Pittenger
No Relationships to Disclose
 
Edward T. Richardson
No Relationships to Disclose
 
Deborah Dillon
Consulting or Advisory Role - Novartis; Oncology Analytics
Travel, Accommodations, Expenses - Novartis
 
Nancy U. Lin
Consulting or Advisory Role - Daiichi Sankyo; Genentech/Roche; Novartis; Puma Biotechnology; Seagen
Research Funding - Genentech; Novartis; Pfizer; Seagen
Patents, Royalties, Other Intellectual Property - Royalties for chapter in Up-to-Date regarding management of breast cancer brain metastases
 
Beth Overmoyer
Research Funding - Eisai (Inst); Genentech (Inst); GTx (Inst); Incyte (Inst)
Travel, Accommodations, Expenses - Novartis
 
Ann H. Partridge
No Relationships to Disclose
 
Eliezer VanAllen
No Relationships to Disclose
 
Elizabeth A. Mittendorf
Honoraria - Physicans' Education Resource
Consulting or Advisory Role - Merck; Peregrine Pharmaceuticals; Sellas Life Sciences; TapImmune Inc.
Research Funding - AstraZeneca (Inst); EMD Serono (Inst); Galena Biopharma (Inst); Genentech/Roche (Inst)
 
Eric P. Winer
Leadership - Leap Therapeutics
Consulting or Advisory Role - GlaxoSmithKline; Lilly; Roche
 
Ian E. Krop
Employment - AMAG Pharmaceuticals (I)
Leadership - AMAG Pharmaceuticals (I)
Stock and Other Ownership Interests - AMAG Pharmaceuticals (I)
Honoraria - Genentech/Roche
Consulting or Advisory Role - Context Therapeutics; Daiichi Sankyo; Genentech/Roche; Macrogenics; Seagen; Taiho Pharmaceutical
Research Funding - Genentech (Inst); Pfizer (Inst)